Message from the Chair
The Department of Pathology is a founding department of the Stanford School of Medicine and one of the leading departments in the United States. Our preeminent faculty spans...
The Dorfman Kempson Fund
Empowering the Next Generation of Pathology Leaders
Help us empower the next generation of scientists to fully leverage all that this new era of discovery has to offer.
As these young scientists go out into the world, the intellectual independence and entrepreneurial fire they gained at Stanford will go with them, and the impact of their achievements will resonate around the globe.
Upcoming Stanford Pathology Events
-
January 28, 2020 Pathology Grand Rounds Guest Speaker: Sing Sing Way, MD, PhD
"Immune Pathogenesis of Prenatal Infection" -
February 03, 2020 ADRC Distinguished Speaker Series Guest Speaker: Helena Chui, MD
“Diabetes mellitus and cognitive impairment” -
February 25, 2020 Pathology Grand Rounds Guest Speaker: Julie Overbaugh, PhD
“Unique Aspects of the Infant Antibody Response to HIV”
Stanford Pathology is now hiring!
- Surgical Pathology
Assistant, Associate or Full Professor of Surgical Pathology - Renal Pathology
Assistant or Associate Professor of Renal Pathology - Clinical Genomics Program
Assistant, Associate, or Co-Laboratory Director - Associate Director of Clinical Chemistry
Open Rank - Hematopathology
Assistant, Associate or Full Professor
-
Stanford Pathologist Greg Charville receives the Stanford Clinical Translational Science Award
Inducted into the KL2 Mentored Career Development Program…
-
Congratulations to this year's winners Stanford Pathology Research Retreat
Announcement and rundown of this year's winners at the Stanford Pathology Research Retreat, 2019…
-
Antiviral treatments lead researchers to develop possible cancer drug
An effort to thwart viral diseases like hepatitis or the common cold led to a new collaboration and a novel class of cancer drugs that appears effective in mice.
-
Cancer research booms, cancer mortality declines, NCI director says
In a speech at Stanford, National Cancer Institute Director Norman Sharpless reported promising cancer mortality trends and described an encouraging landscape for research funding and drug approval.
